This trial is active, not recruiting.

Conditions irritable bowel syndrome, digestive system diseases, gastrointestinal diseases, intestinal diseases, colonic diseases, colonic diseases, functional
Sponsor Chinese PLA General Hospital
Start date January 2006
End date August 2011
Trial size 180 participants
Trial identifier NCT01028898, IBS and metabolism


In the investigators study, the investigators will focus on the screening of the related proteins and miRNA to IBS in order to reveal the possible clues or molecular mechanism for this disorder.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective

Eligibility Criteria

Male or female participants from 18 years up to 60 years old.

Inclusion Criteria: - Patients with symptoms meeting Rome III criteria for diagnosis of IBS-C and IBS-D Exclusion Criteria: - Patients with organic illnesses or a history of major abdominal surgery - Major psychotic episode, mental retardation or dementia - Pregnant women and lactational women - Postinfectious IBS, PI-IBS

Additional Information

Official title Screening and Identification of Abnormal Expression Proteins and miRNA From Colonic Mucosa of Patients With Irritable Bowel Syndrome.
Principal investigator ZHANG Chun-yan, doctor
Description For the proteomic procedures, Our study groups extracted proteins from the cecum and sigmoid colon samples and ran on the two-dimensional gel electrophoresis (2-DE). The proteins on 2-DE were visualized by the silver stain, and then gel maps were scanned and analyzed with the Image Master 2D Elite. The obvious abnormal protein spots were identified by the mass spectrometry. Western blot 、 immunohistochemistry 、 mRNA and miRNA were also performed for further verification of the proteins.
Trial information was received from ClinicalTrials.gov and was last updated in February 2011.
Information provided to ClinicalTrials.gov by Chinese PLA General Hospital.